Gene Biotherapeutics (OTCMKTS:CRXM) Trading Up 3.7%

Gene Biotherapeutics Inc (OTCMKTS:CRXM)’s stock price was up 3.7% during mid-day trading on Monday . The company traded as high as $0.14 and last traded at $0.14, approximately 3,030 shares traded hands during mid-day trading. A decline of 35% from the average daily volume of 4,695 shares. The stock had previously closed at $0.14.

The business has a 50 day moving average price of $0.15 and a 200-day moving average price of $0.13.

About Gene Biotherapeutics (OTCMKTS:CRXM)

Taxus Cardium Pharmaceuticals Group, Inc manages a portfolio of medical technologies in the United States. The company engages in the development and commercialization of Generx, an angiogenic gene therapy product candidate that is in Phase III clinical trial for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.

Further Reading: Understanding Options Trading

Receive News & Ratings for Gene Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gene Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.